A synthetic peptide vaccine directed against the 2β2-2β3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax

Journal of Immunology

Volumn 185, Issue 6, 2010, Pages 3661-3668

  Oscherwitz, Jon ^a,b   Yu, Fen ^a   Cease, Kemp B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; EPITOPE; FREUND ADJUVANT; MULTIPLE ANTIGENIC PEPTIDE; NEUTRALIZING ANTIBODY; PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY SPECIFICITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DOMAIN; RABBIT; T LYMPHOCYTE;

ADMINISTRATION, INHALATION; AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; CELL LINE; FEMALE; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTOZOAN PROTEINS; RABBITS; SPORES, BACTERIAL; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 78649845405     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001749     Document Type: Article

References (62)

1. Lane, H. C., J. L. Montagne, and A. S. Fauci. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7: 1271-1273.
2. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell. Dev. Biol. 19: 45-70.
3. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737.
4. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79: 3162-3166.
5. Kintzer, A. F., K. L. Thoren, H. J. Sterling, K. C. Dong, G. K. Feld, I. I. Tang, T. T. Zhang, E. R. Williams, J. M. Berger, and B. A. Krantz. 2009. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 392: 614-629.
6. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65: 5171-5175.
7. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-430.
8. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19: 4768-4773.
9. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69: 2888-2893.
10. Pitt, M. L., S. Little, B. E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A. M. Friedlander. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87: 304.
11. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-1148.
12. Cybulski, R. J., Jr., P. Sanz, and A. D. O'Brien. 2009. Anthrax vaccination strategies. Mol. Aspects Med. 30: 490-502.
13. Taft, S. C., and A. A. Weiss. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15: 71-75.
14. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health Nations Health 52: 632-645.
15. Little, S. F. 2005. Anthrax vaccines: a development update. BioDrugs 19: 233-245.
16. Little, S. F., B. E. Ivins, W. M. Webster, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24: 2530-2536.
17. Demicheli, V., D. Rivetti, J. J. Deeks, T. Jefferson, and M. Pratt. 1998. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine 16: 880-884.
18. Sever, J. L., A. I. Brenner, A. D. Gale, J. M. Lyle, L. H. Moulton, D. J. West; Anthrax Vaccine Export Committee. 2002. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 11: 189-202.
19. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20: 1412-1420.
20. Rhie, G. E., M. H. Roehrl, M. Mourez, R. J. Collier, J. J. Mekalanos, and J. Y. Wang. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA 100: 10925-10930.
21. Liu, T. H., J. Oscherwitz, B. Schnepp, J. Jacobs, F. Yu, K. B. Cease, and P. R. Johnson. 2009. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors. Mol. Ther. 17: 373-379.
22. Galloway, D., A. Liner, J. Legutki, A. Mateczun, R. Barnewall, and J. Estep. 2004. Genetic immunization against anthrax. Vaccine 22: 1604-1608.
23. Price, B. M., A. L. Liner, S. Park, S. H. Leppla, A. Mateczun, and D. R. Galloway. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69: 4509-4515.
24. Chichester, J. A., K. Musiychuk, P. de la Rosa, A. Horsey, N. Stevenson, N. Ugulava, S. Rabindran, G. A. Palmer, V. Mett, and V. Yusibov. 2007. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 25: 3111-3114.
25. Reason, D., J. Liberato, J. Sun, W. Keitel, and J. Zhou. 2009. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect. Immun. 77: 2030-2035.
26. Zhang, J., J. Xu, G. Li, D. Dong, X. Song, Q. Guo, J. Zhao, L. Fu, and W. Chen. 2006. The 2β2-2β3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem. Biophys. Res. Commun. 341: 1164-1171.
27. Gubbins, M. J., J. D. Berry, C. R. Corbett, J. Mogridge, X. Y. Yuan, L. Schmidt, B. Nicolas, A. Kabani, and R. S. Tsang. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47: 436-443.
28. Abboud, N., M. De Jesus, A. Nakouzi, R. J. Cordero, M. Pujato, A. Fiser, J. Rivera, and A. Casadevall. 2009. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J. Biol. Chem. 284: 25077-25086.
29. Rivera, J., A. Nakouzi, N. Abboud, E. Revskaya, D. Goldman, R. J. Collier, E. Dadachova, and A. Casadevall. 2006. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 74: 4149-4156.
30. Reed, D. S., J. Smoll, P. Gibbs, and S. F. Little. 2002. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis. Cytometry 49: 1-7.
31. Brossier, F., M. Lévy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72: 6313-6317.
32. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56: 1807-1813.
33. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142: 707-715.
34. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and S. H. Leppla. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278: 30936-30944.
35. Albrecht, M. T., H. Li, E. D. Williamson, C. S. LeButt, H. C. Flick-Smith, C. P. Quinn, H. Westra, D. Galloway, A. Mateczun, S. Goldman, et al. 2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 75: 5425-5433.
36. Oscherwitz, J., F. Yu, and K. B. Cease. 2009. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect. Immun. 77: 5509-5518.
37. Oscherwitz, J., F. Yu, J. L. Jacobs, T. H. Liu, P. R. Johnson, and K. B. Cease. 2009. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect. Immun. 77: 3380-3388.
38. Singh, Y., K. R. Klimpel, N. Arora, M. Sharma, and S. H. Leppla. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269: 29039-29046.
39. Novak, J. M., M. P. Stein, S. F. Little, S. H. Leppla, and A. M. Friedlander. 1992. Functional characterization of protease-treated Bacillus anthracis protective antigen. J. Biol. Chem. 267: 17186-17193.
40. Singh, Y., H. Khanna, A. P. Chopra, and V. Mehra. 2001. A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo. J. Biol. Chem. 276: 22090-22094.
41. Miller, C. J., J. L. Elliott, and R. J. Collier. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38: 10432-10441.
42. Gubbins, M. J., L. Schmidt, R. S. Tsang, J. D. Berry, A. Kabani, and D. I. Stewart. 2007. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. J. Immunoassay Immunochem. 28: 213-225.
43. + T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int. Immunol. 3: 997-1003.
44. Chen, Y., and D. L. Boros. 1998. Identification of the immunodominant T cell epitope of p38, a major egg antigen, and characterization of the epitope-specific Th responsiveness during murine schistosomiasis mansoni. J. Immunol. 160: 5420-5427.
45. Fairweather, N. F., V. A. Lyness, D. J. Pickard, G. Allen, and R. O. Thomson. 1986. Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J. Bacteriol. 165: 21-27.
46. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74: 5463-5467.
47. Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace-Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals 32: 17-27.
48. Zaucha, G. M., L. M. Pitt, J. Estep, B. E. Ivins, and A. M. Friedlander. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122: 982-992.
49. Nardin, E. H., J. M. Calvo-Calle, G. A. Oliveira, P. Clavijo, R. Nussenzweig, R. Simon, W. Zeng, and K. Rose. 1998. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 16: 590-600.
50. + T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151: 489-499.
51. Fern, J., and M. F. Good. 1992. Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors. J. Immunol. 148: 907-913.
52. Ahlborg, N., E. H. Nardin, P. Perlmann, K. Berzins, and R. Andersson. 1998. Immunogenicity of chimeric multiple antigen peptides based on Plasmodium falciparum antigens: impact of epitope orientation. Vaccine 16: 38-44.
53. Ingram, R. J., K. K. Chu, G. Metan, B. Maillere, M. Doganay, Y. Ozkul, H. Dyson, E. D. Williamson, L. Baillie, L. U. Kim, et al. 2010. An epitope of Bacillus anthracis protective antigen that is cryptic in rabbits may be immunodominant in humans. Infect. Immun. 78: 2353-, author reply 2353-2354.
54. Marcus, H., R. Danieli, E. Epstein, B. Velan, A. Shafferman, and S. Reuveny. 2004. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect. Immun. 72: 3471-3477.
55. Tross, D., and D. M. Klinman. 2008. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J. Immunol. 181: 5785-5790.
56. Loving, C. L., T. Khurana, M. Osorio, G. M. Lee, V. K. Kelly, S. Stibitz, and T. J. Merkel. 2009. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect. Immun. 77: 255-265.
57. Hermanson, G., V. Whitlow, S. Parker, K. Tonsky, D. Rusalov, M. Ferrari, P. Lalor, M. Komai, R. Mere, M. Bell, et al. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA 101: 13601-13606.
58. Schumacher, W. C., C. A. Storozuk, P. K. Dutta, and A. J. Phipps. 2008. Identification and characterization of Bacillus anthracis spores by multiparameter flow cytometry. Appl. Environ. Microbiol. 74: 5220-5223.
59. Cote, C. K., C. A. Rossi, A. S. Kang, P. R. Morrow, J. S. Lee, and S. L. Welkos. 2005. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb. Pathog. 38: 209-225.
60. Brookmeyer, R., E. Johnson, and R. Bollinger. 2004. Public health vaccination policies for containing an anthrax outbreak. Nature 432: 901-904.
61. Fowler, R. A., G. D. Sanders, D. M. Bravata, B. Nouri, J. M. Gastwirth, D. Peterson, A. G. Broker, A. M. Garber, and D. K. Owens. 2005. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann. Intern. Med. 142: 601-610.
62. Rhie, G. E., Y. M. Park, J. S. Han, J. Y. Yu, W. K. Seong, and H. B. Oh. 2005. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. FEMS Immunol. Med. Microbiol. 45: 341-347.